



## PRESS RELEASE

Code: 00/BIAC/04  
**For Immediate Release!**

**For further information, please contact:**

Julian Abery, Marketing Manager Drug Discovery  
+44 (0)7808 900732

**Scientific/Trade Press Enquiries:**

Nikul Odedra, HCC.De Facto Group  
+44 (0) 207 496 3300

# **Biacore Enters Collaboration with SmithKline Beecham**

**Further deal validates the value of Biacore's  
technology to the drug discovery industry**

**Uppsala, Sweden, February 22, 2000.** Biacore International AB (Biacore) (SSE: BCOR; Nasdaq: BCOR) today announced that it has entered into a collaborative agreement with SmithKline Beecham Pharmaceuticals (LSE: SB.L), whereby the pharmaceutical giant will evaluate Biacore's new prototype high performance system in preclinical and ADME\* drug screening studies. The collaboration marks yet another milestone in Biacore's commitment to providing novel analytical systems to help the pharmaceutical industry increase the flow of high-quality drug leads reaching the clinic.

The collaboration is second in a series of validation deals aimed at fully optimizing the new high performance system for applications downstream of high-throughput

drug screening. The first deal was signed with Millennium Pharmaceuticals Inc. in December 1999.

As part of the agreement, SmithKline Beecham will rigorously test the device in studies to measure its utility in generating critical drug discovery data.

“This collaboration, like the deal we recently entered into with Millennium Pharmaceuticals, endorses the undoubted value of our biosensor technology to the drug discovery industry,” said Lars-Göran Andrén, Biacore's President and Chief Executive Officer. He added, “Securing SmithKline Beecham as a validation partner means that we will benefit from the expertise of a major pharmaceutical research effort as we seek to optimize the ability of our new high-performance system to overcome the key bottlenecks downstream of high-throughput screening.”

*\* ADME stands for Absorption, Distribution, Metabolism and Excretion and represents the pharmaceutical characterization of new drug candidates.*

*[Reuters: BCOR.N]*

– Ends –

*This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.*

---

*Notes to editors:*

*Biacore is a global market leader in affinity-based biosensor technology with its own sales operations in the U.S., across Europe, in Japan, Australia and New Zealand. The technology is protected by a strong patent portfolio. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery as the prime area for future growth. Based in Uppsala, Sweden, the company is listed on the OM Stockholm Exchange and Nasdaq in the U.S. In 1999 the company has sales of SEK 340.4 million and an operating income of SEK 67.6 million.*

*Further information on Biacore can be found on the web: [www.biacore.com](http://www.biacore.com)*

*Address and phone:*

*Biacore International AB  
Rapsgatan 7, SE-754 50 Uppsala, SWEDEN  
Phone: +46 (0)18-675700 Fax: +46 (0)18-150111  
[info@biacore.com](mailto:info@biacore.com)*